Table 5.
Robustness study for the developed method (n = 5).
| Parameter studied | Salmeterol xinafoate |
Fluticasone propionate |
||
|---|---|---|---|---|
| SDa | CVa | SDa | CVa | |
| Composition of mobile phase | 130.4 | 1.49 | 358.9 | 2.3 |
| Volume of mobile phase | 127.8 | 1.46 | 344.3 | 2.21 |
| Time from spotting to development (5–60 min) | 55.29 | 0.63 | 256.8 | 1.65 |
| Time from development to scanning (5–60 min) | 40.9 | 1.1 | 22.2 | 0.40 |
SD and CV were calculated from the peak areas of densitograms.